6.76
price up icon2.27%   0.15
after-market Handel nachbörslich: 6.76
loading
Schlusskurs vom Vortag:
$6.61
Offen:
$6.67
24-Stunden-Volumen:
5.45M
Relative Volume:
0.65
Marktkapitalisierung:
$1.17B
Einnahmen:
$847.25M
Nettoeinkommen (Verlust:
$-284.86M
KGV:
-2.952
EPS:
-2.29
Netto-Cashflow:
$-112.35M
1W Leistung:
+4.32%
1M Leistung:
-4.38%
6M Leistung:
-21.12%
1J Leistung:
-47.88%
1-Tages-Spanne:
Value
$6.52
$6.90
1-Wochen-Bereich:
Value
$6.23
$6.90
52-Wochen-Spanne:
Value
$5.01
$17.81

Novavax Inc Stock (NVAX) Company Profile

Name
Firmenname
Novavax Inc
Name
Telefon
240-268-2000
Name
Adresse
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Name
Mitarbeiter
1,992
Name
Twitter
@novavax
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
NVAX's Discussions on Twitter

Vergleichen Sie NVAX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NVAX
Novavax Inc
6.76 1.17B 847.25M -284.86M -112.35M -2.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Novavax Inc Stock (NVAX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-28 Eingeleitet BTIG Research Buy
2024-07-30 Herabstufung JP Morgan Neutral → Underweight
2024-05-10 Hochstufung BofA Securities Underperform → Neutral
2024-05-10 Hochstufung JP Morgan Underweight → Neutral
2023-08-09 Hochstufung B. Riley Securities Neutral → Buy
2023-04-20 Herabstufung TD Cowen Outperform → Market Perform
2023-03-01 Herabstufung B. Riley Securities Buy → Neutral
2023-01-09 Bestätigt B. Riley Securities Buy
2022-12-30 Bestätigt H.C. Wainwright Buy
2022-12-02 Eingeleitet Jefferies Hold
2022-09-22 Herabstufung JP Morgan Neutral → Underweight
2022-05-20 Eingeleitet BofA Securities Underperform
2022-02-23 Bestätigt B. Riley Securities Buy
2022-02-22 Fortgesetzt Jefferies Buy
2022-01-21 Eingeleitet Cowen Outperform
2021-05-12 Herabstufung JP Morgan Overweight → Neutral
2020-12-14 Eingeleitet Jefferies Buy
2020-08-06 Bestätigt H.C. Wainwright Buy
2020-08-05 Hochstufung JP Morgan Neutral → Overweight
2020-08-05 Herabstufung Ladenburg Thalmann Neutral → Sell
2020-07-16 Bestätigt H.C. Wainwright Buy
2020-07-08 Herabstufung Ladenburg Thalmann Buy → Neutral
2020-06-29 Bestätigt B. Riley FBR Buy
2020-06-29 Bestätigt H.C. Wainwright Buy
2020-06-05 Hochstufung JP Morgan Underweight → Neutral
2020-05-28 Bestätigt B. Riley FBR Buy
2020-05-12 Bestätigt H.C. Wainwright Buy
2020-04-30 Bestätigt H.C. Wainwright Buy
2019-11-27 Fortgesetzt B. Riley FBR Buy
2019-08-14 Bestätigt H.C. Wainwright Buy
2019-02-28 Herabstufung Piper Jaffray Overweight → Underweight
2018-12-18 Eingeleitet Ladenburg Thalmann Buy
2018-12-11 Eingeleitet Oppenheimer Outperform
2018-11-26 Hochstufung Piper Jaffray Neutral → Overweight
2018-09-21 Hochstufung JP Morgan Underweight → Overweight
2018-03-29 Hochstufung Seaport Global Securities Neutral → Buy
Alle ansehen

Novavax Inc Aktie (NVAX) Neueste Nachrichten

pulisher
Jun 17, 2025

Novavax (NVAX): Citi Downgrades to Sell Amid Pipeline Worries - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Novavax stock slips as Citi issues Sell rating (NVAX:NASDAQ) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigrou - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Novavax (NVAX) Coverage Initiated with 'Sell' Rating by Citigroup | NVAX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citi initiates Novavax stock with sell rating on strategy shift concerns - Investing.com UK

Jun 17, 2025
pulisher
Jun 17, 2025

Novavax (NVAX) Receives Initial 'Sell' Rating from Citi | NVAX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 13, 2025

Novavax: New Vaccine, Same Old StoryStill A Sell (NASDAQ:NVAX) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 12, 2025

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Novavax: positive results for Covid/flu vaccine - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response - Yahoo Finance

Jun 12, 2025
pulisher
Jun 12, 2025

Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals - The Pharma Letter

Jun 12, 2025
pulisher
Jun 12, 2025

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial - Pipelinereview

Jun 12, 2025
pulisher
Jun 12, 2025

RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Novavax at Goldman Sachs Healthcare Conference: Strategic Shift to R&D Focus - Investing.com Nigeria

Jun 12, 2025
pulisher
Jun 11, 2025

RFK Jr. picks eight new members to CDC vaccine advisory panel - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax's COVID-19-Influenza Combination and Stand-alone Influen - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NVAX) Phase 3 Trial Shows Promising Results in Vaccine Study | NVAX Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax reports positive results for COVID-19 and flu vaccine candidates By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Novavax, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax's COVID-flu combo vaccine shows strong immune response in trial - Reuters

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NVAX) Reports Promising Results for COVID-19-Flu Vaccine Combo - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Tesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fall By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax's Covid-Influenza Combo, Standalone Flu Vaccines Show 'Robust Immune Responses' in Phase 3 Study - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax stock gains on data for COVID-flu shot (NVAX:NASDAQ) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax reports positive results for COVID-19 and flu vaccine candidates - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NVAX) Reports Positive Results for COVID-Influenza Comb - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax Reports Promising Phase 3 Vaccine Trial Results - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax (NVAX) Reports Positive Results for COVID-Influenza Combo Vaccine Trial | NVAX Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Novavax Breakthrough: Phase 3 Trial Reveals Strong Results for First-of-Kind COVID-Flu Combo Vaccine - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

Vaccine makers steady despite RFK Jr.'s removal of CDC expert panel (PFE:NYSE) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Vaccine stocks muted as investors assess Kennedy's overhaul of key panel - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Vaccine Stocks Stay Steady Despite US Health Shake-Up - Finimize

Jun 10, 2025
pulisher
Jun 10, 2025

Recombinant Vaccine Market is Booming Worldwide with - openPR.com

Jun 10, 2025
pulisher
Jun 10, 2025

American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance - Benzinga

Jun 10, 2025
pulisher
Jun 09, 2025

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

RFK Jr. removing, replacing all members of CDC vaccine advisory panel (MRNA:NASDAQ) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 09, 2025

Where are the Opportunities in (NVAX) - news.stocktradersdaily.com

Jun 09, 2025
pulisher
Jun 05, 2025

Investor Network: Novavax, Inc to Host Earnings Call - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

July 25th Options Now Available For Novavax (NVAX) - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

LigaChem Biosciences adopts U.S. Novavax technology for next-gen ADCs - Chosunbiz

Jun 05, 2025
pulisher
Jun 02, 2025

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals - Benzinga

Jun 02, 2025
pulisher
May 31, 2025

Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stoc - GuruFocus

May 31, 2025
pulisher
May 30, 2025

US CDC continues to recommend COVID vaccines for children, contradicts Kennedy - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

RFK Jr. Drops COVID Vaccine Recommendation For Healthy Kids, But Experts Warn Of Major Risks - Benzinga

May 30, 2025
pulisher
May 29, 2025

Novavax to Participate in Upcoming Investor Conferences - Quantisnow

May 29, 2025

Finanzdaten der Novavax Inc-Aktie (NVAX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Novavax Inc-Aktie (NVAX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Alton Gregg H
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
28,805
King Rachel K.
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
25,190
Rodgers Richard J
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
24,690
MOTT DAVID M
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
60,890
DOUGLAS RICHARD
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
54,340
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):